Suscribirse

Can the Sarcoidosis Health Questionnaire predict the long-term outcomes in Japanese sarcoidosis patients? - 16/03/19

Doi : 10.1016/j.rmed.2019.01.001 
Kiminobu Tanizawa a , Tomohiro Handa b, , Sonoko Nagai c , Toru Oga a , Takeshi Kubo d , Yutaka Ito e , Kensaku Aihara f , Kohei Ikezoe b , Akihiko Sokai b , Yoshinari Nakatsuka b , Toyohiro Hirai b , Kazuo Chin a , Michiaki Mishima f , Takateru Izumi c
a Department of Respiratory Care and Sleep Control Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan 
b Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan 
c Kyoto Central Clinic, Clinical Research Center, Kyoto, Japan 
d Department of Diagnostic Imaging and Nuclear Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan 
e Department of Respiratory Medicine, Allergy and Clinical Immunology, School of Medical Sciences, Nagoya City University, Nagoya, Japan 
f Department of Respiratory Medicine, Saiseikai-Noe Hospital, Osaka, Japan 

Corresponding author. Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawaharacho, Sakyo-ku, Kyoto, 606-8507, Japan.Department of Respiratory MedicineGraduate School of MedicineKyoto University54 Shogoin KawaharachoSakyo-kuKyoto606-8507Japan

Abstract

Rationale

The Sarcoidosis Health Questionnaire (SHQ) is the first sarcoidosis-specific health status questionnaire ever developed. Worse health status, as evaluated by the SHQ, may indicate higher risk for deterioration in the following 5 years.

Objectives

To evaluate the association between SHQ scores and deterioration defined clinically at 5-year follow-up.

Methods

122 patients with biopsy-supported sarcoidosis completed the SHQ and underwent evaluation with respect to organ involvement, chest radiograph, electrocardiogram, serum biomarker measurements, pulmonary function tests, and echocardiogram. Of these 122, 88 (72.1%) were available for pulmonary, cardiac, and non-pulmonary, non-cardiac deterioration assessment during the following 5 years.

Measurements and main results

Five-year deterioration was observed in 20 patients (23%). The SHQ total score was significantly associated with 5-year deterioration, after adjusting for cardiac involvement at baseline, with adjusted odds ratio (OR) of 0.54 (95% confidence interval [95% CI], 0.29–0.99). The association of the total SHQ with 5-year outcome was not significant when adjusted for left ventricular ejection fraction (LVEF) at baseline (adjusted OR, 0.61 [0.32–1.16]), whereas LVEF was significantly associated with 5-year outcome (adjusted OR, 0.92 [0.86–0.99]). The association between total SHQ score and 5-year deterioration was marginal when adjusted for baseline usage of systemic corticosteroid (CS)/immunosuppressive (IS) agents (adjusted OR, 0.58 [0.31–1.10]), whereas systemic CS/IS usage significantly predicted 5-year deterioration (adjusted odds ratio [OR], 3.46 [1.12–10.7]). There was a marginal correlation between the total SHQ and LVEF (rho = 0.19, p = 0.07) and a weak association between the total SHQ and systemic CS/IS usage (rho = −0.23, p = 0.03). The Physical Functioning domain scores of the SHQ were significantly associated with 5-year deterioration (adjusted OR, 0.45–0.51).

Conclusions

Worse health status, as assessed by the SHQ score, can be a risk factor for 5-year deterioration of sarcoidosis, although usage of the CS/IS at baseline and lower LVEF at baseline are more predictive of 5-year deterioration.

El texto completo de este artículo está disponible en PDF.

Highlights

Worse health status is a risk factor for 5-year deterioration of sarcoidosis.
The Sarcoidosis Health Questionnaire is predictive for long-term outcomes.
Systemic therapy at baseline is associated with long-term deterioration.
Light ventricular dysfunction is also a risk factor for 5-year deterioration.

El texto completo de este artículo está disponible en PDF.

Keywords : Sarcoidosis, Health-related quality of life, Health status, Questionnaire, Outcomes


Esquema


© 2019  Elsevier Ltd. Reservados todos los derechos.
Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 149

P. 1-8 - mars 2019 Regresar al número
Artículo siguiente Artículo siguiente
  • The development of sarcoidosis in patients receiving daclizumab: A case series from multiple clinical trials
  • Marc A. Judson, Brett M. Elicker, Thomas V. Colby, Sooyeon Kwon, Elizabeth de Windt, Spyros Chalkias, Claudia Prada, Karen Smirnakis, Priya Singhal

¿Ya suscrito a @@106933@@ revista ?